THERAPY DOSSIER · th-a431bb6ae29a

Sinomenine

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL248095 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Cucoline; Kukoline; Sinomenin; Sinomenine
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05764304 ↗PHASE3unknown

Sinomenine vs Glucocorticoid for Early Knee Osteoarthritis

Knee Osteoarthritis

Enrolment: 328 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26795599 ↗2016Reported benefit

Sinomenine activation of Nrf2 signaling prevents hyperactive inflammation and kidney injury in a mouse model of obstructive nephropathy.

MouseOther

Model: Obstructive nephropathy (mouse model)

Sinomenine reduced kidney damage, inflammatory responses and renal oxidative stress in an Nrf2-dependent manner and modulated macrophage polarisation.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…